Patents by Inventor Mark D. Wittman

Mark D. Wittman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isofuranone compounds useful as HPK1 inhibitors
    Patent number: 11166959
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Erika M. V. Araujo, Yan Chen, Bireshwar Dasgupta, Andrew P. Degnan, Matthew D. Hill, Godwin Kwame Kumi, Harold A. Mastalerz, Mark D. Wittman, Bradley C. Pearce, Guifen Zhang
  • ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS
    Publication number: 20200390776
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 5, 2018
    Publication date: December 17, 2020
    Inventors: Erika M.V. Araujo, Yan Chen, Bireshwar Dasgupta, Andrew P. Degnan, Matthew D. Hill, Godwin Kwame Kumi, Harold A. Mastalerz, Mark D. Wittman, Bradley C. Pearce, Guifen Zhang
  • Imidazo-pyridazine derivatives as casein kinase 1 ?/? inhibitors
    Patent number: 9956220
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Selvakumar Kumaravel, Arul Mozhi Selvan Subbiah Karupplah, Shilpa Holehatti Maheshwarappa, Chandrasekhar Reddy Rachamreddy, Mark D. Wittman
  • IMIDAZO-PYRIDAZINE DERIVATIVES AS CASEIN KINASE 1 DELTA/EPSILON INHIBITORS
    Publication number: 20170137427
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 18, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Upender Velaparthi, Selvakumar Kumaravel, Arul Mozhi Selvan Subbiah Karupplah, Shilpa Holehatti Maheshwarappa, Chandrasekhar Reddy Rachamreddy, Mark D. Wittman
  • Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors
    Patent number: 9598423
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mallikarjuna Rao Mettu, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • Substituted imidazoles as casein kinase 1 D/E inhibitors
    Patent number: 9556179
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Dharmpal S. Dodd, Anthony J. Sampognaro, Mark D. Wittman, Selvakumar Kumaravel, Dibakar Mullick, Peiying Liu, Chandrasekhar Reddy Rachamreddy
  • SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20160311824
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 27, 2016
    Inventors: Upender Velaparthi, Chetan Padmakar Dame, Peiying Liu, Mark D Wittman, Bradley C. Pearce, Erika M.V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mallikarjuna Rao Mettu, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
    Patent number: 9475817
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 25, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Dharmpal S. Dodd, Peiying Liu, Christopher P. Mussari, Mark D. Wittman, Selvakumar Kumaravel, Dibakar Mullick
  • NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20160122358
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mallikarjuna Rao Mettu, Arul Mozhi Subbiah Karuppiah, Subba Reddy Bandreddy, Nagalakshmi Pulicharla, Rajesh Onkardas Bora, Shilpa Maheshwarappa Holehatti, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Kumar Sistla
  • Substituted pyrazolo-piperazines as casein kinase 1 ?/? inhibitors
    Patent number: 9273058
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mettu Mallikarjuna Rao, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20150344480
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 3, 2015
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Upender Velaparthi, Chen Padmakar Dame, Dharmpal s. Dodd, Peiying Liu, Christopher P. Mussari, Mark D. Wittman, Selvakumar Kumaravel, Dibakar Mullick
  • NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20150344481
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 3, 2015
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Dharmpal S. Dodd, Anthony J. Sampognaro, Mark D. Wittman, Selvakumar Kumaravel, Dibakar Mullick, Peiying Liu, Chandrasekhar Reddy Rachamreddy
  • NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS
    Publication number: 20150133428
    Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Peiying Liu, Mark D. Wittman, Bradley C. Pearce, Erika M. V. Araujo, Bireshwar Dasgupta, Jalathi Surendran Nair, Sakthi Kumaran Janakiraman, Chandrasekhar Reddy Rachamreddy, Mettu Mallikarjuna Rao, Arul Mozhi Selvan Subbiah Karuppiah, Bandreddy Subba Reddy, Pulicharla Nagalakshmi, Rajesh Onkardas Bora, Shilpa Holehatti Maheshwarappa, Selvakumar Kumaravel, Dibakar Mullick, Ramesh Sistla
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8592579
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: November 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Triazine kinase inhibitors
    Patent number: 8415340
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: April 9, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Peiying Liu, Mark D. Wittman, David R. Langley
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8343999
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Marco Dodier, Stephan Roy, Kurt Zimmermann, Xiaopeng Sang, Mark D. Wittman, David R. Langley, Ramkumar Rajamani
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20120302747
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: August 7, 2012
    Publication date: November 29, 2012
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8263765
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Kurt Zimmermann, Xiaopeng Sang
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8198438
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anti-cancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: June 12, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anthony J. Sampognaro, Mark D. Wittman
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8148400
    Abstract: The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley